A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer

Yi Ying Wu, Hsin Yi Liu, Tzu Chuan Huang, Jia Hong Chen, Ping Ying Chang, Ching Liang Ho, Tsu Yi Chao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1793-1798
Number of pages6
JournalOncology Letters
Volume10
Issue number3
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Neutropenia
Myelopoiesis
Breast Neoplasms
Drug Therapy
Placebos
Adjuvant Chemotherapy
Granulocytes
Interleukin-6
Quality of Life
Blood Cell Count
Hematopoiesis
Complex Mixtures
Soybeans
Doxorubicin
Cyclophosphamide
Polysaccharides
Neutrophils
Safety
Serum
Therapeutics

Keywords

  • Black soybean
  • Breast cancer
  • Chemotherapy
  • Myelopoiesis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer. / Wu, Yi Ying; Liu, Hsin Yi; Huang, Tzu Chuan; Chen, Jia Hong; Chang, Ping Ying; Ho, Ching Liang; Chao, Tsu Yi.

In: Oncology Letters, Vol. 10, No. 3, 01.09.2015, p. 1793-1798.

Research output: Contribution to journalArticle

Wu, Yi Ying ; Liu, Hsin Yi ; Huang, Tzu Chuan ; Chen, Jia Hong ; Chang, Ping Ying ; Ho, Ching Liang ; Chao, Tsu Yi. / A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer. In: Oncology Letters. 2015 ; Vol. 10, No. 3. pp. 1793-1798.
@article{18e23521ef394ea5987fda8e2ddd02e8,
title = "A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer",
abstract = "EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy.",
keywords = "Black soybean, Breast cancer, Chemotherapy, Myelopoiesis",
author = "Wu, {Yi Ying} and Liu, {Hsin Yi} and Huang, {Tzu Chuan} and Chen, {Jia Hong} and Chang, {Ping Ying} and Ho, {Ching Liang} and Chao, {Tsu Yi}",
year = "2015",
month = "9",
day = "1",
doi = "10.3892/ol.2015.3492",
language = "English",
volume = "10",
pages = "1793--1798",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer

AU - Wu, Yi Ying

AU - Liu, Hsin Yi

AU - Huang, Tzu Chuan

AU - Chen, Jia Hong

AU - Chang, Ping Ying

AU - Ho, Ching Liang

AU - Chao, Tsu Yi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy.

AB - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy.

KW - Black soybean

KW - Breast cancer

KW - Chemotherapy

KW - Myelopoiesis

UR - http://www.scopus.com/inward/record.url?scp=84937437156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937437156&partnerID=8YFLogxK

U2 - 10.3892/ol.2015.3492

DO - 10.3892/ol.2015.3492

M3 - Article

AN - SCOPUS:84937437156

VL - 10

SP - 1793

EP - 1798

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -